Emerging evidence · Grade B
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c)
Score
60 / 100
Class
Mitochondrial-derived peptide
Mechanism
AMPK / exercise-mimetic
Status
Investigational
TL;DR
01
A 16-amino-acid peptide encoded within mitochondrial DNA (a 'mitochondrial-derived peptide'), discovered in 2015 and promoted as an 'exercise mimetic.'
02
In mice it activates the metabolic master-switch AMPK, prevents diet- and age-induced insulin resistance, and reduces obesity — a genuinely interesting metabolic biology.
03
In humans, though, the evidence is associational (blood MOTS-c levels track with metabolic health and fitness) — there are no interventional human trials.
04
So the 'exercise in a vial' framing runs well ahead of the human evidence.
05
It is not approved and is sold as a research chemical with no purity or dosing guarantees.
Human interventional trials
None
no dosing RCTs
Preclinical (mice)
Strong
insulin sensitivity, anti-obesity
Human data
Associational
levels track fitness/metabolism
Mechanism
AMPK activation
metabolic master-switch
Approval
None
research chemical
Part 01 · How it works
Mechanism.
MOTS-c is a tiny peptide written into the mitochondrial genome itself — a sign that mitochondria send out their own signals. When given to mice, it flips on AMPK, the cell's energy-sensing master-switch, mimicking some of the metabolic effects of exercise: better insulin sensitivity, resistance to diet-induced obesity. That's why it's marketed as an 'exercise mimetic.' The important caveat is that this is mouse biology plus human correlation studies — no one has run a trial giving MOTS-c to people and measuring what happens.
A signal your mitochondria naturally send that, in mice, mimics some benefits of a workout. In humans we can see the signal correlates with fitness — but no one has tested whether injecting it does anything.
Mitochondrial-derived peptide
Encoded by a short open reading frame in the mitochondrial 12S rRNA.
AMPK activation
Inhibits the folate cycle/de novo purine synthesis, activating AMPK, primarily in skeletal muscle (mouse data).
Metabolic effects
Prevented age- and high-fat-diet-induced insulin resistance and diet-induced obesity in mice.
Evidence stage
Preclinical (mice) + human association studies; no human interventional trials.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for MOTS-c. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Standard dose
5-10 mg/week
Subcutaneous injection · 3–5x per week or daily (e.g., 1 mg/day, 5-on/2-off)
Duration
8 weeks typical cycle
·
Community metabolic protocols run ~5 mg/week (1 mg/day, 5-on/2-off) up to ~10 mg/week, consistent with the range shown.
·
The landmark mouse study dosed 0.5 mg/kg/day intraperitoneally (Lee 2015) — mouse metabolic doses do not translate directly to humans.
·
MOTS-c is an endogenous mitochondrial-derived peptide; no human interventional dose is established and research supply has no purity/dose guarantee.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Human tolerability
No interventional human safety data.
Uncharacterized
Serious · rare
Long-term human safety
No human supplementation safety data.
Unknown
Metabolic effects
AMPK activation is powerful; effects of exogenous dosing in humans unstudied.
Theoretical
Product-quality risk
Research-chemical supply; purity/dose unknown.
Source-dependent
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to MOTS-c or any component
×
Active malignancy (effects on cellular metabolism in cancer cells unknown)
Relative · discuss first
!
Pregnancy or breastfeeding — no data
!
Diabetes on glucose-lowering therapy — theoretical additive metabolic effects, unstudied
!
Anyone expecting proven benefit — no human interventional trials
Interactions
Metformin
Both activate AMPK pathway; theoretical additive metabolic effects and hypoglycemia risk
Moderate
Insulin
MOTS-c improves insulin sensitivity; may potentiate insulin effect and increase hypoglycemia risk
Moderate
Exercise mimetics (AICAR)
Additive AMPK activation; clinical significance unknown but theoretical excessive metabolic stress
Minor
Labs to monitor
Fasting Glucose & Insulin
Baseline and monthly
MOTS-c improves insulin sensitivity and glucose uptake
HbA1c
Baseline and every 3 months
Track glycemic improvements
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CK (Creatine Kinase)
Baseline and at 4 weeks
Exercise mimetic effects — monitor muscle stress
Lactate
Baseline (optional)
MOTS-c affects AICAR and AMPK pathway, altering energy metabolism
Part 04 · Evidence
How strong is the evidence?
60
Grade B
Grade B, Emerging. MOTS-c has a fascinating mechanism and strong mouse metabolic data, plus human association studies — but no interventional human trials, so its marketed benefits remain unproven in people.
Mechanistic plausibility
Novel, well-characterized AMPK/exercise-mimetic biology.
80
Human evidence
Association studies only; no interventional human trials.
40
Safety & tolerability
Endogenous peptide; no human safety dataset for supplementation.
62
Durability
No human outcome data.
50
Independence
Studied by the originating group and others; human work is observational.
62
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2015
Cell Metabolism Flagged
MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Identified MOTS-c as a mitochondrial-derived peptide that activates AMPK and, in mice, prevented age- and diet-induced insulin resistance and diet-induced obesity.
Cell + mouse metabolic study (discovery paper) · Foundational discovery in cells/mice; not human interventional evidence.
PMID 25738459 ↗
High (preclinical)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
'Exercise mimetic' claims outrun the human evidence
Mechanism limit Cell Metabolism · 2015
MOTS-c's metabolic benefits are established in mice; human data is limited to associations (levels correlating with fitness/metabolic health). No trial has given MOTS-c to people and measured outcomes.
What this means: Marketing it as 'exercise in a vial' overstates the case. In humans it is a promising signal, not a demonstrated intervention.
PMID 25738459 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Not approved
No approved product; research chemical.
Grey-market; unregulated
European Union
Not approved
No approved product.
N/A
United Kingdom
Not approved
No approved product.
N/A
Canada
Not approved
No approved product.
N/A
The Peptide Column takes no affiliate commission from any source. MOTS-c has no human interventional trials and is not approved anywhere; consumer supply is research-grade and unregulated, and its marketed benefits are unproven in people. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
What is my current metabolic health baseline (fasting glucose, insulin, HbA1c)?
02
How does MOTS-c compare to lifestyle interventions for metabolic improvement?
03
Are there any contraindications given my current medications?
04
What dosing protocols have been used in the available human studies?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance · Cell Metabolism, 2015 · PMID 25738459 ↗
- 02. PubMed. MOTS-c discovery and human association literature